Center for Applied Medical Research (CIMA)
If you are the contact person for this centre and you wish to make any changes, please contact us.
Researcher in the Gene Therapy and Regulation of Gene Expression Programme and Director of Innovation and Transfer at Cima University of Navarra
Professor of Immunology at the University of Navarra, CIMA researcher and co-director of the Department of Immunology and Immunotherapy at the Clínica Universidad de Navarra.
Senior Researcher of the Gene Therapy in Neurodegenerative Diseases Programme at the Centre for Applied Medical Research (CIMA), University of Navarra
Researcher of the Gene Therapy and Regulation of Gene Expression Programme at Cima (Centre for Applied Medical Research) University of Navarra
News of cancer vaccines proliferate in the media, yet only one such vaccine has been approved - against metastatic prostate cancer - and is no longer in use. However, only one as such has been approved - against metastatic prostate cancer - and it is no longer in use. Are the attention and hopes justified? What do they consist of and how are they similar to traditional ones? Are they preventive or therapeutic? Can they be universal or will they be extremely personalised? How much will they cost? This is what we know today.
Two preclinical studies published in the journal Science have introduced new bioengineered modifications to CAR-T cells in an attempt to make them more potent and safer in their anti-tumour action. These variations allow their activity to be enhanced only in the vicinity of the tumour or their actions to be regulated on demand.
Research to be published in the journal Nature identifies and characterizes the cells responsible for relapse in colon cancer. In addition, it proposes revising clinical guidelines and administering immunotherapy before surgery to try to avoid them
Research has tested a gene therapy method that targets overactive cells to treat epilepsy in mice. The results are published in the journal Science.
A study published in the journal Nature Medicine has tested a therapy based on CAR-T cells - T lymphocytes modified in the laboratory - to treat five patients with systemic lupus erythematosus who did not respond to conventional treatments. According to the study, the symptoms subsided in all of them and the improvement was maintained throughout the duration of the study.